Your browser doesn't support javascript.
loading
Racial inequities and rare CFTR variants: Impact on cystic fibrosis diagnosis and treatment.
Wu, Malinda; Davis, Jacob D; Zhao, Conan; Daley, Tanicia; Oliver, Kathryn E.
Afiliación
  • Wu M; Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA.
  • Davis JD; Pediatric Institute, Children's Healthcare of Atlanta, Atlanta, GA, USA.
  • Zhao C; Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, GA, USA.
  • Daley T; Interdisciplinary Graduate Program in Quantitative Biosciences, Georgia Institute of Technology, Atlanta, GA, USA.
  • Oliver KE; Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA.
J Clin Transl Endocrinol ; 36: 100344, 2024 Jun.
Article en En | MEDLINE | ID: mdl-38765466
ABSTRACT
Cystic fibrosis (CF) has been traditionally viewed as a disease that affects White individuals. However, CF occurs among all races, ethnicities, and geographic ancestries. The disorder results from mutations in the CF transmembrane conductance regulator (CFTR). Varying incidence of CF is reported among Black, Indigenous, and People of Color (BIPOC), who typically exhibit worse clinical outcomes. These populations are more likely to carry rare CFTR variants omitted from newborn screening panels, leading to disparities in care such as delayed diagnosis and treatment. In this study, we present a case-in-point describing an individual of Gambian descent identified with CF. Patient genotype includes a premature termination codon (PTC) (c.2353C>T) and previously undescribed single nucleotide deletion (c.1970delG), arguing against effectiveness of currently available CFTR modulator-based interventions. Strategies for overcoming these two variants will likely include combinations of PTC suppressors, nonsense mediated decay inhibitors, and/or alternative approaches (e.g. gene therapy). Investigations such as the present study establish a foundation from which therapeutic treatments may be developed. Importantly, c.2353C>T and c.1970delG were not detected in the patient by traditional CFTR screening panels, which include an implicit racial and ethnic diagnostic bias as these tests are comprised of mutations largely observed in people of European ancestry. We suggest that next-generation sequencing of CFTR should be utilized to confirm or exclude a CF diagnosis, in order to equitably serve BIPOC individuals. Additional epidemiologic data, basic science investigations, and translational work are imperative for improving understanding of disease prevalence and progression, CFTR variant frequency, genotype-phenotype correlation, pharmacologic responsiveness, and personalized medicine approaches for patients with African ancestry and other historically understudied geographic lineages.
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Idioma: En Revista: J Clin Transl Endocrinol Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Bases de datos: MEDLINE Idioma: En Revista: J Clin Transl Endocrinol Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos